Ribosome biogenesis: an emerging druggable pathway for cancer therapeutics

Frédéric Catez¹, Nicole Dalla Venezia¹, Virginie Marcel¹, Christiane Zorbas², Denis L.J. Lafontaine² and Jean-Jacques Diaz¹

¹ Univ Lyon, Université Claude Bernard Lyon 1, Inserm U1052, CNRS UMR5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, 69008 Lyon, France.

² RNA Molecular Biology, ULB Cancer Research Center (U-CRC), Center for Microscopy and Molecular Imaging (CMMI), Fonds National de la Recherche (F.R.S./FNRS) and Université Libre de Bruxelles (ULB), BioPark Campus, 6041 Gosselies, Belgium

co-senior authors

* corresponding author: Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR5286, 28 rue Laennec, 69008 Lyon. France. Phone: +33-478782819, fax: +33-478782720. Jean-Jacques.DIAZ@lyon.unicancer.fr

Running title: Targeting ribosomes as anticancer therapy

Keywords: Ribosome; Ribosome biogenesis; rRNA modification; Chemotherapy; Cancer

Document statistics:

Abstract: 133 words

Main text: 26,238 words

Figures and tables: 1 figure

References: 98

Abstract

Ribosomes are nanomachines essential for protein production in all living cells. Ribosome synthesis increases in cancer cells to cope with a rise in protein synthesis and sustain unrestricted growth. This increase in ribosome biogenesis is reflected by severe morphological alterations of the nucleolus, the cell compartment where the initial steps of ribosome biogenesis take place. Ribosome biogenesis has recently emerged as an effective target in cancer therapy, and several compounds that inhibit ribosome production or function, killing preferentially cancer cells, have entered clinical trials. Recent research indicates that cells express heterogeneous populations of ribosomes and that the composition of ribosomes may play a key role in tumorigenesis, exposing novel therapeutic opportunities. Here, we review recent data demonstrating that ribosome biogenesis is a promising druggable pathway in cancer therapy, and discuss future research perspectives.

Keywords: Ribosome; Ribosome biogenesis; rRNA modification; Chemotherapy; Cancer

1. Introduction: Cancer cells are addicted to ribosome production

In eukaryotes, the initial steps of ribosome production take place within specialized nuclear domains called nucleoli. Nucleoli are highly dense nuclear structures that assemble around the nucleolar organizers (NORs) containing the genes coding for ribosomal RNAs (rRNAs) [1]. For

1 many years, changes in nucleolar morphology, nucleolar size, and number of nucleoli per nucleus
2 have been recognized as hallmarks of malignity and tumor aggressiveness [2]. The analysis of
3 nucleolar morphology, typically after specific staining (e.g. silver nitrate-based AgNOR), has been
4 used by pathologists to establish the tumorigenic potential of cells in patient biopsies [2–5].
5 However, significant technical limitations, including in quantification and reproducibility, have
6 prevented the routine implementation of such techniques by pathologists. Recently, the production
7 of specific algorithms has addressed several of these limitations by providing tools to characterize
8 nucleolar disruption both qualitatively (i.e. distinguishing patterns of disruption) and quantitatively
9 (i.e. measuring severity of disruption), and by defining a precise numerical index: the ‘index of
10 nucleolar disruption’ or iNo score [6,7]. Hopefully, such tools will be transformed into clinical
11 applications in order to extend the use of nucleolar morphology to disease diagnosis and prognosis,
12 and to integrate the nucleolus as a biomarker for improved patient stratification.

13 The alterations of nucleolar morphology observed in cancer cells directly reflect the hyper
14 activation of ribosome production. Importantly, it appears that tumor cells are addicted to increased
15 ribosome production (and increased translational activity), since inhibition of these processes is
16 generally cytotoxic. It is largely assumed that cancer cells become addicted to ribosomes owing to
17 their enhanced need for protein production to sustain their unrestricted growth. The fact that
18 inhibitors of translation, such as the one targeting the translation initiation machinery (mTOR
19 inhibitors, eIF4F complex inhibitors), kill cancer cells supports such a concept of addiction [8–10].

20 In addition, the abnormal oncogenic signaling of cancer cells prevents the efficient feedback
21 control that coordinates the synthesis of rRNAs and r-proteins, and eventually leads to nucleolar
22 stress and apoptosis (see below). Increased ribosome biogenesis is a general trend in cancer cells
23 [11–14], which is important for cell transformation and tumorigenesis, (see [15–17]), and it remains
24 unclear why some tumor cells rely more than others on ribosome production and protein synthesis.

1 Mechanistically, increased ribosome production in cancer cells is caused by the dysregulation of
2 the three RNA polymerases by molecular mechanisms involving cancer-promoting proteins,
3 including major oncogenic and tumor suppressive pathways, like c-Myc, mTOR, p53, pRb and
4 PTEN (reviewed in details in [14,18]).

5 Ribosome biogenesis is a complex process involving the synthesis, modification, assembly, and
6 transport of eighty-four core ribosomal components: four rRNAs and eighty ribosomal proteins (r-
7 proteins) (Figure 1) [19]. It is highly energy-consuming, involves all three RNA polymerases (Pol),
8 and most cell compartments as it is initiated in the nucleolus, progresses to the nucleoplasm, and
9 ends in the cytoplasm [20]. Three of the four mature rRNAs are produced from a single long
10 polycistronic precursor synthesized by RNA polymerase I (Pol I) requiring extensive processing
11 (RNA cleavage), the fourth rRNA, namely the 5S, is produced by RNA Pol III [19], while r-
12 proteins are encoded in mRNAs synthesized by Pol II. All of these components work
13 synergistically to ensure their faithful assembly into precursor (pre-) ribosomal subunits. This
14 requires the participation of over 200 assembly factors. Each of these steps is closely regulated and
15 intimately interconnected, to such a level that inhibiting one may severely impact another [21].
16 Finally, important quality control is exerted all along the pathway to ensure that only properly
17 assembled ribosomes are produced [22].

18 Ribosomes were traditionally considered to be a ‘monolithic block’, and it was believed that cells
19 exclusively produce a single type of ribosome. It was recently shown that cells produce
20 heterogeneous populations of ribosomes, the composition of which may differ, producing
21 functional consequences on translation [23]. For instance, ribosomes may differ because their
22 rRNAs are differentially modified (rRNAs contain over 200 modifications including the abundant
23 2'-O-methylation, and pseudouridylation, as well as a dozen other base methylations, see below),
24 or because an r-protein is absent or replaced by tissue-specific isoforms [24,25]. This, in turn, may

1 impact the selection of mRNAs that ribosomes translate, thus influencing either normal processes,
2 such as cell differentiation or embryogenesis, or disease etiology, such as cancer initiation and
3 progression [26]. In this review, we will refer to “ribosome variants” when we discuss
4 compositionally different ribosomes, to “specialized ribosomes”, when a specific function in the
5 translation of specific mRNA transcripts has been attributed to these different ribosomes, and to
6 “cancer ribosomes”, when specialized ribosomes have been associated with tumorigenesis. Despite
7 the current efforts to systematically identify ribosome assembly factors in human cells [27–31], the
8 fine molecular mechanisms and the kinetics of processing, assembly, nuclear export and quality
9 control remain largely unexplored in humans compared to budding yeast (the historical reference
10 model) [19,32].

11 Until recently, targeting ribosomes to develop anticancer therapeutic strategies was not seriously
12 envisaged for several reasons. Firstly, because human ribosome biogenesis is a highly complex
13 process, the coordinated regulation of which is not fully deciphered. Secondly, because it involves
14 the contribution of hundreds of cellular factors, many of which remain to be identified. Thirdly,
15 and most importantly, because inhibiting ribosome biogenesis or function was expected to
16 indistinctively kill healthy and diseased cells. Surprisingly, however, cancer cells are more
17 sensitive to treatments that inhibit ribosome production.

18 In this review, we summarize recent evidence supporting the notion that targeting ribosome
19 biogenesis and/or function in cancer cells represents a promising strategy to develop specific
20 powerful anticancer drugs. So far, such strategies have led to the development of several molecules
21 that interfere with distinct steps of ribosome production and function, and some of these molecules
22 have entered clinical trials (Figure 1).

2. Targeting ribosome biogenesis for therapeutic intervention

2.1 Targeting ribosome biogenesis at the level of rRNA synthesis

1) Rationale and proof-of-concept

The rationale for targeting ribosome biogenesis in cancer cells is based on the general observation that cancer cells produce more ribosomes and are thus likely to be more vulnerable to a reduction in ribosome production than healthy cells [13]. Historically, such a strategy was first attempted by using inhibitors of Pol I such as actinomycin D [33]. However, the limited specificity of actinomycin D, and its important toxicity towards cells, prevented its further development. Nonetheless, the effect on ribosome biogenesis of thirty-six drugs belonging to different chemical categories and routinely used in chemotherapeutic regimens was systematically investigated revealing that half of them displayed strong inhibitory effects on ribosome biogenesis by interfering specifically with either rRNA synthesis or pre-rRNA processing [34]. Quite unexpectedly, inhibition of ribosome biogenesis appears to represent the primary mode of action of some of these well-established anticancer compounds, as it was recently reported in the myc-driven Eμ-Myc Cdkn2aArf^{-/-} lymphoma model for several platinum derivatives including oxaliplatin [35]. These data prompted the idea that targeting ribosome production may be a promising approach to develop innovative anticancer drugs.

Proof-of-concept that targeted therapies which selectively inhibit ribosomal subunit biogenesis are efficient at killing cancer cells was made independently by Australian and American teams. They characterized several compounds, namely: CX-5461, CX-3543, and BMH-21 [36–39]), which selectively inhibit the function of Pol I (Figure 1 – Box 1). CX derivatives and BMH-21 act *via* distinct mechanisms. CX derivatives are G-quadruplex (G4) DNA motif binders while BMH-21

binds to GC-rich DNA sequences [36,37,39,40]. Both G4 and GC-rich motifs are abundant in rDNA. CX derivatives inhibit the function of Pol I by preventing the binding of nucleolin and UBF (Upstream Binding Factor) [37,38], both of which are important for RNA synthesis, to Pol I promoters, while BMH-21 triggers the proteasomal-dependent degradation of the large catalytic subunit of Pol I [39]. Despite being DNA-binding molecules, these compounds were initially shown to not induce DNA damage in cultured cells, a feature that support their selectivity toward Pol I activity [36,37,39,40]. However, a recent study on DNA repair deficient cells raised the possibility that DNA damage might also contribute to their toxicity, at least in cells with particular genetic background ([41] and see below). In the original studies, the compounds were tested *in vitro* on a large panel of cancer cell lines representative of different types of cancers (NCI60 panel or an extended panel). For each of the three compounds, there was no association between the cancer of origin of the cell lines and the observed IC₅₀ values, indicating that they do not have an organ-specific activity [37–39]. Yet, the IC₅₀ values ranged from 90- to more than a 100-folds among cell lines for CX-5461 and BMH-21, respectively. This shows that these compounds have a selective toxicity toward cells with particular molecular profiles, which remain to be characterized. Once characterized, these molecular profiles might lead to identification of tumor subtypes that would benefit from treatment with these compounds. To date, CX-5461 has been the most extensively studied, and its anticancer activity has been reported in multiple cancer backgrounds, including: leukemia, lymphomas and myelomas [36,42–44], prostate [45], osteosarcoma [46], ovary [47] and neuroblastoma [48], illustrating the potentially broad applicability of such compounds. In addition to interfering with the function of Pol I, CX derivatives also cause severe replication and DNA repair issues since they stabilize G4 DNA motifs which form naturally within guanine-rich DNA sequences and consist of a four-stranded helical structure [41]. The tumor suppressor BRCA2 is important for replication fork stabilization and for

1 DNA damage repair, including for repairing G-quadruplexes. Treatment with CX-3543 or with CX-
2 5461 eventually kills any cell, irrespective of its origin, but cancer cells, in particular those that
3 have lost their ability to repair DNA damage, are particularly sensitive to treatment with both CX
4 derivatives [41]. This is typically the case for BRCA-deficient cancer cells, and for polyclonal
5 patient-derived xenografts (PDX), including tumors resistant to PARP inhibitors (poly ADP ribose
6 polymerase) and/or to platinum salts [41]. The deleterious effect of CX-5461 on BRCA2-deficient
7 cells was reported in two colorectal cell lines, one ovarian cell line, in breast tumor cells, and in
8 bone osteosarcoma cells, vouching for the general applicability of treatments with G4 stabilizers
9 in DNA-repair deficient background, while not calling the effect on Pol I activity into question
10 [41].

11 An important consequence of inhibiting drug-induced ribosome biogenesis is the activation of a
12 regulatory loop known as nucleolar stress [49]. The nucleolar stress response is a p53-dependent
13 anti-tumoral pathway activated following a dysfunction in ribosome biogenesis [50]. Briefly, in
14 normal cells, the antitumor protein p53 is maintained at a low level as it is constitutively targeted
15 to the proteasome for degradation by Hdm2-mediated ubiquitination. Upon stress inhibiting
16 ribosome biogenesis, free unassembled ribosomal components accumulate. This is notably the case
17 of the uL5-uL18-5S rRNA trimeric complex which titrates Hdm2, sequestering it away from p53
18 [51,52]. The consequence of Hdm2 titration is the stabilization of p53 and the activation of a cell
19 death program leading to the killing of the stressed cell. [footnote: Note that on the basis of
20 structural conservation between the three kingdoms of life, a coherent nomenclature has recently
21 been proposed for r-proteins [53]. In this unified nomenclature, RPL11 and RPL5 have been
22 renamed uL5 and uL18, respectively]. It is quite remarkable that among the eighty ribosomal
23 proteins, uL5 and uL18 are the most important for maintaining the structure of the nucleolus [6].
24 In addition, the cytotoxic activity of these compounds is not limited to p53-dependent apoptosis,

1 since other cell death modalities were reported including necrosis, senescence and autophagy, thus
2 broadening the potential application of inhibitors of ribosome biogenesis for killing cancer cells
3 [36–39]. However, the fine molecular mechanisms underlying these effects have as yet not been
4 elucidated. Furthermore, the deleterious effects of CX-5461 have been observed in cells and
5 polyclonal PDX models that lack p53 [41].

6 The rationale for establishing ribosome biogenesis as a druggable pathway in cancer therapeutics
7 further resides in the observation that CX-derivatives and BMH-21 drugs seem to preferentially
8 kill cancer cells, leaving “normal” untransformed cells less affected. For example, the CX-5461
9 compound displays an IC₅₀ of around 5 µM and 3 nM in non-transformed cells (e.g. BJ-hTert
10 fibroblasts) and cancer cells (e.g. EOL-1 leukemia cells), respectively, while retaining the same
11 Pol I inhibitory activity [38]. Drug selectivity is also supported by animal studies, in which these
12 compounds displayed efficient antitumor activity without impacting the weight of mice over the 5-
13 week time course of the treatment [36,39,40]. In these studies, growth inhibition was observed
14 using xenografts of pancreatic cancer MIA PaCa-2 cells (CX-3543 and CX-5461), melanoma A375
15 cells (CX-5461 and BMH-21), and colorectal cancer HCT116 cells (BMH-21) [36–40]. Evaluation
16 of CX-5461 in advanced phase I clinical trial for patients with BRCA1/2 deficient tumors is
17 ongoing in Canada (NCT02719977). CX-3543 has been assessed in solid and neuroendocrine
18 tumors, and lymphomas as phase I/II studies in the US, and no other trial is currently active
19 (<https://clinicaltrials.gov>). In conclusion, independent works have demonstrated that the
20 pharmacological inhibition of ribosome biogenesis is an efficient means of preferentially killing
21 cancer cells. This was a turning point in the demonstration that the nucleolus is a bona fide target
22 for anti-cancer intervention [54,55].

23 24 2) Limitations.

1 Although targeting ribosome production by inhibiting the function of Pol I appears to be appealing,
2 several limitations have been identified that will have to be overcome to fulfill the requirements of
3 further clinical developments. Firstly, not all cell lines are sensitive to Pol I inhibitors (see NCI60
4 response [37–39]), and this is irrespective of their p53 status. Therefore, it is crucial to better
5 understand the pathways modulating the sensitivity of cells to these inhibitors. Secondly, the tested
6 compounds only have a limited selectivity towards rRNA genes. Indeed, both CX-derivatives and
7 BMH-21 are DNA binding compounds that are able to directly interact with any DNA sequence
8 that is GC-rich or contains G-quadruplex, which means that they can bind elsewhere in the genome
9 than onto rDNA. As such, these compounds are not specific to Pol I, they preferentially affect Pol
10 I because rDNA genes are enriched in GC- and G-quadruplex-motifs. Thirdly, there are reported
11 cases of acquired resistance to CX-5461, indicating that the anticancer activity of the drug can
12 somehow be bypassed.

15 2.2 Targeting ribosome biogenesis at other levels than RNA synthesis

16 rRNA synthesis is only one of several steps of ribosome biogenesis that represents a druggable
17 target, another being pre-rRNA processing. Processing depends on dozens of trans-acting factors
18 which can either be proteinaceous or ribonucleic in nature. In addition to the actual catalytic
19 activities, directly responsible for RNA processing (i.e. the endo- and exoribonucleolytic
20 activities), many factors contribute to the proper folding of pre-rRNAs to enable them to acquire a
21 cleavage-competent conformation. This is notably the case of the C/D box small nucleolar RNAs
22 (snoRNAs) U3 and U8 which interact with the pre-rRNA through the formation of Watson-Crick
23 base-pairing interactions. U3 and U8 are essential for early and late pre-rRNA processing reactions
24 leading to the formation of small and large ribosomal subunits, respectively [56]. Using a mouse

1 xenograft model, it was recently shown that aggressive cancer cells in which the expression of U3
2 or U8 was silenced lost their tumorigenic potential once implanted into the flanks of nude animals
3 [56]. When tumors formed, these were not only smaller but also more heterogeneous in
4 composition as a consequence of healthy tissue repopulating the microenvironment. Increased
5 tumor heterogeneity, as established by positive emission tomography that relies on the use of a
6 metabolic tracer, is considered to be a positive clinical parameter owing to the presence of healthy
7 tissues [56]. Consistently, knockdown of fibrillarin, one of the essential proteins of the U3/U8 C/D
8 box complex, resulted in the reduced growth of MCF7 xenografts [57].

9 Other steps of ribosome biogenesis that may also be targeted are ribosome assembly and chemical
10 modification of its components. There are only a few known pharmacological inhibitors of
11 ribosome assembly. The best characterized being diazaborin, which inhibits the formation of the
12 large ribosomal subunit at a late stage in budding yeast [58]. The search is on for similar active
13 compounds on human cells. Finally, the chemical modifications of rRNAs also constitute a crucial
14 step of ribosome biogenesis that can be targeted to design anticancer drugs since they lead to the
15 production of cancer ribosomes (see below).

18 **3. Targeting the function of ribosomes**

21 Owing to the central role of ribosomes in modulating gene expression, innovative therapeutics
22 inhibiting their function could also be pertinent. Indeed, this would represent a novel means of
23 reducing the translational capacity of cells, which plays a primary role in tumorigenesis (reviewed
24 in [11]). The control of translation has also been proposed as a novel target to circumvent resistance

1 to targeted therapies, for example by inhibiting the eIF4F translation initiation complex in the
2 context of anti-BRAF and anti-MEK resistance [9]. However, similarly to inhibiting ribosomal
3 subunit biogenesis, a major challenge remains to be addressed, namely the level of specificity of
4 such an inhibition. Indeed, (i) would it target a particular transcript or a subset of transcripts? (ii)
5 Would it preferentially target diseased than healthy cells? Despite these concerns, this is a rapidly
6 developing field of research, and several molecules are already in use to treat human diseases,
7 including neurodevelopmental syndromes and cancer [59]. Indeed, homoharringtonine, a natural
8 plant alkaloid extracted from the Japanese plum-yew tree *Cephalotaxus harringtonii*, is an FDA-
9 approved drug in the treatment of chronic myeloid leukemia traditionally used in Chinese medicine
10 (Figure 1 – Box 3), which functions by inhibiting translation. [footnote: Homoharringtonine is also
11 known as omocetaxine mepesuccinate or Synribo®].

12 Alternatively, molecules that simultaneously target ribosome production (by blocking synthesis of
13 components, or their assembly) and function (by blocking an active site on the ribosome) (Figure
14 1 – Boxes 2 and 3) could be developed. One such case is haemanthamine, a natural alkaloid
15 extracted from Daffodil bulbs, the anticancer properties of which have been used in folk medicine
16 for centuries and have only recently been deciphered [60]. Indeed, it was demonstrated that this
17 molecule targets both ribosome function, by sterically blocking translation, and ribosome
18 production, by inhibiting RNA processing specifically; this latter property providing the added
19 advantage of a potent activation of the nucleolar stress response leading to strong p53 stabilization
20 [60].

21 Combination therapy is routinely used in oncology and could enhance ribosome inhibition
22 approaches. A direct effect of combining drugs is that the molecules are administered at lower
23 concentrations thereby reducing their level of toxicity. The first attempts at combining Pol I
24 inhibitor treatments with other drugs *in vitro* have revealed promising results, for example by

combining CX-5461 with the mTOR inhibitor Everolimus on Myc-driven lymphoma xenograft [61], or by combining CX-5461 and the pan-PIM-kinase inhibitor CX-6258 on prostate cancer PDX [45]. Furthermore, combining molecules that target ribosome biogenesis and/or function with other anticancer treatments could prevent resistance and prolong the effects of individual drugs. For instance, as discussed above, inhibition of ribosome biogenesis results in an increase in the intracellular pool of free ribosomal proteins, which plays a major role in promoting apoptosis. Considering that free ribosomal proteins have a short half-life [62], drugs that target the proteasomes could be used to stabilize them. Finally, reducing the ribosome pool of cancer cells may weaken their metabolism and might render them more sensitive to stresses induced by other drugs.

4. Targeting “cancer ribosomes”: myth or reality?

Today we are facing a paradigm shift with the demonstration that cells do not produce ribosomes with a unique composition, but instead produce a variety of ribosomes that differ in their protein and RNA composition [24,63]. Ribosome composition was shown to vary in r-proteins or rRNAs according to the status of the cell, environmental conditions, developmental stages, or physiological and pathological conditions [64–73]. Interestingly, ground-breaking studies have demonstrated changes in rRNA composition in cancer cells supporting to the existence of cancer-associated ribosome variants, exhibiting altered rRNA 2'-O-methylation [69,70]. In addition, mutations of the DKC1 gene encoding the pseudouridine synthase dyskerin were identified in dyskeratosis congenita patients, which are characterized by an increased cancer susceptibility.

1 These patients display an altered rRNA pseudouridine content [72,74]. Hence, these findings
2 substantiate the notion of cancer ribosomes (see definition in the introduction section). Continuous
3 technological advances in mapping rRNA modifications and characterizing the ribosomal
4 proteome will be instrumental in identifying cancer-specific ribosomal signatures and reinforcing
5 the cancer ribosome hypothesis.

6 Among the different types of RNA modifications, 2'-O-methylation (2'-O-Me) is the most
7 abundant on eukaryotic rRNA with 55 and 106 sites mapped in yeast and in human rRNA,
8 respectively [71,73,75–77]. 2'-O-Me patterns of such cancer ribosomes were shown to be different
9 from those of their healthy counterparts, i.e. the level of 2'-O-Me at some of the sites was different
10 [70]. Importantly, 2'-O-Me provides an unanticipated "plasticity" to rRNA and ribosomes, since
11 changes in the 2'-O-Me pattern is a molecular means to affect ribosome composition, which in turn
12 contributes to modulating ribosomal activity [69–71,78–81]. For instance, modulation of 2'-O-Me,
13 may provide functional specificity to cancer ribosomes, favoring the translation of mRNAs with
14 key roles in tumorigenesis, cell survival and resistance to chemotherapeutic treatments [70,71].
15 Interestingly, modifications in 2'-O-Me are associated with alterations of internal ribosome entry
16 site (IRES)-dependent translation initiation, which is preferentially activated under stress (e.g.
17 hypoxia or nutrient deprivation). The mRNA of many major genes implicated in tumorigenesis
18 contain an IRES-element, including oncogenes (c-Myc), tumor suppressors (p53), growth factors
19 and their receptors (IGF-1R, VEGF, FGF) and apoptosis modulators (XIAP, Bcl-xl) [11,82]. The
20 alteration of 2'-O-Me levels was associated with increased IRES-dependent translation initiation
21 of c-Myc, FGF, VEGF and IGF-1R [70]. How such regulatory mechanisms contribute to
22 tumorigenesis *in vivo* remains to be explored. Interestingly, a similar role is attributed to
23 pseudouridylation, which, remarkably, affects a different set of IRES-elements compared to 2'-O-

Me, and further supports the notion that chemical modifications of rRNA plays a central role in modulating the translational capacity of ribosomes, notably during tumorigenesis [74,83,84].

In humans, 2'-O-Me of rRNA is carried out by the methyl transferase fibrillarin associated with the RNA-binding protein 15.5 kDa and the core proteins NOP56 and NOP58 [85,86]. Methylation at each site is guided by snoRNAs from the C/D box snoRNA family, which carry a complementary sequence to the target rRNA [87]. As the mechanisms of partial rRNA modification remain largely unknown, it is interesting that progressively reducing the concentration of fibrillarin in cells only impacts a subset of the 106 2'-O-methylated nucleotides, and that these mostly correspond to positions that are naturally hypomodified [71,73]. This suggests that hypo-modification is regulated by limiting the amounts of specific functional snoRNPs [71,73,86]. Moreover, of these 106 2'-O-Me sites, several are sensitive to the presence of p53 in cells [70,73], which may indicate that modulation of 2'-O-Me levels contribute to regulating cell proliferation or to other aspects of the tumor suppressive functions promoted by p53. In addition, fibrillarin controls the amount of ribosome production through various molecular mechanisms, including rDNA histone methylation, pre-rRNA processing, and pre-rRNA modification [88], and its expression is controlled by p53 [70,73]. Therefore, targeting such a master regulator of ribosome biogenesis could also be a promising approach to interfere with the production of ribosomes. However, to our knowledge no inhibitors of fibrillarin have so far been described.

Lastly, developing drugs directly targeting specific ribosome variants, such as cancer ribosomes, can seriously be envisaged in view of the mode of action of several antibiotics that bind to highly specific ribosomal structures [89]. In particular, recent structural analysis of prokaryotic and eukaryotic ribosomes demonstrated that selectivity of ligand [footnote: By 'ligand', we refer to any molecule that can bind to the ribosome, i.e. tRNA, r-protein, translational factor, or small molecule inhibitors, including antibiotics and compounds active towards eukaryotic ribosomes] binding is

1 often provided by subtle differences in the structure of the ribosome [60,90–95]. For instance, the
2 anticancer compound haemanthamine, presented above, binds exclusively to eukaryotic ribosomes,
3 since its binding site is slightly different in bacterial compared to human ribosomes, and is
4 consequently only active in human cells [60]. Interestingly, resistance to antibiotics often relies on
5 chemical modifications of the ribosomes [90,96], illustrating that changes as faint as a single
6 chemical modification are sufficient to prevent the binding of small molecule inhibitors. This
7 provides the proof-of-concept that it may be possible to develop antibiotic-like molecules to target
8 the ribosomes that accumulate in cancer cells providing they exhibit structural features that
9 distinguish them, even slightly, from those of healthy cells.

12 **5. Conclusions and future directions**

15 In this commentary, we presented evidence that ribosome biogenesis and function have emerged
16 as novel cellular processes that can be efficiently targeted to treat cancer. This description included
17 strategies that are currently under evaluation in clinical trials (RNA synthesis inhibition), as well
18 as those that we deem should be further investigated in the future (targeting ribosome variants with
19 small molecule inhibitors). However, we are but at the dawn of anticancer ribosome therapeutics,
20 and many essential questions remain, the most important being why cancer cells are more sensitive
21 than healthy ones to drugs that inhibit ribosome production and/or function. We speculate that the
22 propensity of cancer cells to rely on more abundant ribosome production and increased protein
23 synthesis to sustain their unrestricted cell growth renders them more vulnerable to cellular
24 alterations of ribosome levels. Alternatively, cancer cells may be rewired by compositionally and

1 functionally different ribosomes, offering a theory based on the preponderance of the ‘quality’ of
2 the ribosomes produced, rather than their ‘quantity’, in tumorigenesis.

3 So far, inhibition of ribosome biogenesis has only been tested in a relatively limited number of
4 cancer models, and should thus be evaluated more broadly, in particular in cancers with higher
5 therapeutic demands (e.g. advanced pancreatic or colorectal cancer, triple negative breast cancer,
6 and melanoma) or in those displaying stronger proliferative traits.

7 8 9 **Acknowledgement**

10 We thank Brigitte Manship (CRCL) for critical reading and editing of the manuscript. FC is a
11 CNRS research fellow. VM and JJD are Inserm research fellows. CZ is an F.R.S./FNRS research
12 fellow. JJD laboratory is supported by Inserm, CNRS, Université Claude Bernard Lyon 1, Centre
13 Léon Bérard, Agence Nationale pour la Recherche (RIBOMETH ANR-13-BSV8-0012-01),
14 Programmes d'Actions Intégrées de Recherche (PAIR Sein, RiboTEM, ARC_INCa_LNCC_7625),
15 Ligue Nationale contre le Cancer, Ligue contre le Cancer comité départemental (Drôme, Rhône,
16 Isère, Puy-de-Dôme, Allier) and Fondation ARC pour la Recherche sur le Cancer (2016120486).
17 DLJL laboratory is supported by the Université Libre de Bruxelles (ULB), the Fonds National de
18 la Recherche (F.R.S./FNRS), the Walloon Region (DGO6), and the Fédération Wallonie-Bruxelles.

19 20 **Conflict of interest**

21 The authors declare no conflict of interest related to the content of this manuscript.

References

- [1] H. Mangan, M.Ó. Gailín, B. McStay, Integrating the genomic architecture of human nucleolar organizer regions with the biophysical properties of nucleoli., *FEBS J.* 284 (2017) 3977–3985. doi:10.1111/febs.14108.
- [2] M. Derenzini, L. Montanaro, D. Treré, What the nucleolus says to a tumour pathologist, *Histopathology.* 54 (2009) 753–762. doi:10.1111/j.1365-2559.2008.03168.x.
- [3] J.E. Quin, J.R. Devlin, D. Cameron, K.M. Hannan, R.B. Pearson, R.D. Hannan, Targeting the nucleolus for cancer intervention, *Biochim Biophys Acta.* 1842 (2014) 802–816. doi:10.1016/j.bbadis.2013.12.009.
- [4] R. Kaushik, S. Sharma, V. Mahajan, A. Gulati, B.B. Sharma, AgNORs in endometrial lesions, *Indian J Pathol Microbiol.* 42 (1999) 451–454. <http://www.ncbi.nlm.nih.gov/pubmed/11127377>.
- [5] M. Derenzini, The AgNORs., *Micron.* 31 (2000) 117–20. <http://www.ncbi.nlm.nih.gov/pubmed/10588056> (accessed May 15, 2018).
- [6] E. Nicolas, P. Parisot, C. Pinto-Monteiro, R. de Walque, C. De Vleeschouwer, D.L.J. Lafontaine, Involvement of human ribosomal proteins in nucleolar structure and p53-dependent nucleolar stress., *Nat. Commun.* 7 (2016) 11390. doi:10.1038/ncomms11390.
- [7] V. Stamatopoulou, P. Pascaline Parisot, C. De Vleeschouwer, D. L.J. Lafontaine, Use of the iNo score to discriminate normal from altered nucleolar morphology, with applications in basic cell biology and potential in human disease diagnostics, *Nat. Protoc.* (n.d.).
- [8] Q.B. She, E. Halilovic, Q. Ye, W. Zhen, S. Shirasawa, T. Sasazuki, D.B. Solit, N. Rosen, 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors, *Cancer Cell.* 18 (2010) 39–51.

doi:10.1016/j.ccr.2010.05.023.

- [9] L. Boussemart, H. Malka-Mahieu, I. Girault, D. Allard, O. Hemmingsson, G. Tomasic, M. Thomas, C. Basmadjian, N. Ribeiro, F. Thuaud, C. Mateus, E. Routier, N. Kamsu-Kom, S. Agoussi, A.M. Eggermont, L. Désaubry, C. Robert, S. Vagner, eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies., *Nature*. 513 (2014) 105–109. doi:10.1038/nature13572.
- [10] A.C. Hsieh, M. Costa, O. Zollo, C. Davis, M.E. Feldman, J.R. Testa, O. Meyuhas, K.M. Shokat, D. Ruggero, Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E, *Cancer Cell*. 17 (2010) 249–261. doi:10.1016/j.ccr.2010.01.021.
- [11] D. Ruggero, Translational control in cancer etiology, *Cold Spring Harb Perspect Biol*. 5 (2013) a012336. doi:10.1101/cshperspect.a012336.
- [12] D. Ruggero, P.P. Pandolfi, Does the ribosome translate cancer?, *Nat Rev Cancer*. 3 (2003) 179–192. doi:10.1038/nrc1015.
- [13] D. Ruggero, Revisiting the nucleolus: From marker to dynamic integrator of cancer signaling, *Sci. Signal*. 5 (2012) 5–7. doi:10.1126/scisignal.2003477.
- [14] S. Whittaker, M. Martin, R. Marais, All roads lead to the ribosome, *Cancer Cell*. 18 (2010) 5–6. doi:10.1016/j.ccr.2010.06.008.
- [15] J. Pelletier, G. Thomas, S. Volarevi, Ribosome biogenesis in cancer: New players and therapeutic avenues, *Nat. Rev. Cancer*. 18 (2017) 51–63. doi:10.1038/nrc.2017.104.
- [16] M. Barna, A. Pusic, O. Zollo, M. Costa, N. Kondrashov, E. Rego, P.H. Rao, D. Ruggero, Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency, *Nature*. 456 (2008) 971–975. doi:10.1038/nature07449.
- [17] L. Montanaro, D. Trere, M. Derenzini, Changes in ribosome biogenesis may induce cancer

by down-regulating the cell tumor suppressor potential, *Biochim Biophys Acta.* 1825
(2012) 101–110. doi:10.1016/j.bbcan.2011.10.006.

[18] D. Drygin, W.G. Rice, I. Grummt, The RNA Polymerase I Transcription Machinery: An
Emerging Target for the Treatment of Cancer, *Annu. Rev. Pharmacol. Toxicol.* 50 (2010)
131–156. doi:10.1146/annurev.pharmtox.010909.105844.

[19] A.K. Henras, C. Plisson-Chastang, M.F. O'Donohue, A. Chakraborty, P.E. Gleizes, An
overview of pre-ribosomal RNA processing in eukaryotes, *Wiley Interdiscip Rev RNA.* 6
(2015) 225–242. doi:10.1002/wrna.1269.

[20] R.N. Nazar, Ribosomal RNA processing and ribosome biogenesis in eukaryotes, *IUBMB
Life.* 56 (2004) 457–465. doi:10.1080/15216540400010867.

[21] D.L. Lafontaine, Noncoding RNAs in eukaryotic ribosome biogenesis and function, *Nat
Struct Mol Biol.* 22 (2015) 11–19. doi:10.1038/nsmb.2939.

[22] C. Peña, E. Hurt, V.G. Panse, Eukaryotic ribosome assembly, transport and quality control,
Nat. Struct. Mol. Biol. 24 (2017) 689–699. doi:10.1038/nsmb.3454.

[23] N.R. Genuth, M. Barna, The Discovery of Ribosome Heterogeneity and Its Implications
for Gene Regulation and Organismal Life., *Mol. Cell.* 71 (2018) 364–374.
doi:10.1016/j.molcel.2018.07.018.

[24] W. V Gilbert, Functional specialization of ribosomes?, *Trends Biochem Sci.* 36 (2011)
127–132. doi:10.1016/j.tibs.2010.12.002.

[25] N.R. Genuth, M. Barna, Heterogeneity and specialized functions of translation machinery:
from genes to organisms., *Nat. Rev. Genet.* 19 (2018) 431–452. doi:10.1038/s41576-018-
0008-z.

[26] Z. Shi, M. Barna, Translating the Genome in Time and Space: Specialized Ribosomes,
RNA Regulons, and RNA-Binding Proteins, *Annu. Rev. Cell Dev. Biol.* 31 (2015) 31–54.

doi:10.1146/annurev-cellbio-100814-125346.

- [27] J.S. Andersen, C.E. Lyon, A.H. Fox, A.K.L. Leung, Y.W. Lam, H. Steen, M. Mann, A.I. Lamond, Directed proteomic analysis of the human nucleolus., *Curr. Biol.* 12 (2002) 1–11. <http://www.ncbi.nlm.nih.gov/pubmed/11790298> (accessed September 5, 2018).
- [28] A. Scherl, Y. Couté, C. Déon, A. Callé, K. Kindbeiter, J.-C. Sanchez, A. Greco, D. Hochstrasser, J.-J. Diaz, Functional proteomic analysis of human nucleolus., *Mol. Biol. Cell.* 13 (2002) 4100–9. doi:10.1091/mbc.e02-05-0271.
- [29] L. Tafforeau, C. Zorbas, J.L. Langhendries, S.T. Mullineux, V. Stamatopoulou, R. Mullier, L. Wacheul, D.L. Lafontaine, The complexity of human ribosome biogenesis revealed by systematic nucleolar screening of Pre-rRNA processing factors, *Mol Cell.* 51 (2013) 539–551. doi:10.1016/j.molcel.2013.08.011.
- [30] K.I. Farley-Barnes, K.L. McCann, L.M. Ogawa, J. Merkel, Y. V Surovtseva, S.J. Baserga, Diverse Regulators of Human Ribosome Biogenesis Discovered by Changes in Nucleolar Number., *Cell Rep.* 22 (2018) 1923–1934. doi:10.1016/j.celrep.2018.01.056.
- [31] L. Badertscher, T. Wild, C. Montellese, L.T. Alexander, L. Bammert, M. Sarazova, M. Stebler, G. Csucs, T.U. Mayer, N. Zamboni, I. Zemp, P. Horvath, U. Kutay, Genome-wide RNAi Screening Identifies Protein Modules Required for 40S Subunit Synthesis in Human Cells., *Cell Rep.* 13 (2015) 2879–91. doi:10.1016/j.celrep.2015.11.061.
- [32] J.L. Woolford, S.J. Baserga, Ribosome biogenesis in the yeast *Saccharomyces cerevisiae*, *Genetics.* 195 (2013) 643–681. doi:10.1534/genetics.113.153197.
- [33] U. Hollstein, Actinomycin. Chemistry and mechanism of action, *Chem. Rev.* 74 (1974) 625–652. doi:10.1021/cr60292a002.
- [34] K. Burger, B. Muhl, T. Harasim, M. Rohrmoser, A. Malamoussi, M. Orban, M. Kellner, A. Gruber-Eber, E. Kremmer, M. Holzel, D. Eick, Chemotherapeutic drugs inhibit ribosome

1 biogenesis at various levels, *J Biol Chem.* 285 (2010) 12416–12425.

2 doi:10.1074/jbc.M109.074211.

- 3 [35] P.M. Bruno, Y. Liu, G.Y. Park, J. Murai, C.E. Koch, T.J. Eisen, J.R. Pritchard, Y. Pommier,
4 S.J. Lippard, M.T. Hemann, A subset of platinum-containing chemotherapeutic agents kills
5 cells by inducing ribosome biogenesis stress, *Nat. Med.* 23 (2017) 461–471.

6 doi:10.1038/nm.4291.

- 7 [36] M.J. Bywater, G. Poortinga, E. Sanij, N. Hein, A. Peck, C. Cullinane, M. Wall, L. Cluse,
8 D. Drygin, K. Anderes, N. Huser, C. Proffitt, J. Bliesath, M. Haddach, M.K. Schwaebe,
9 D.M. Ryckman, W.G. Rice, C. Schmitt, S.W. Lowe, R.W. Johnstone, R.B. Pearson, G.A.
10 McArthur, R.D. Hannan, Inhibition of RNA polymerase I as a therapeutic strategy to
11 promote cancer-specific activation of p53, *Cancer Cell.* 22 (2012) 51–65.

12 doi:10.1016/j.ccr.2012.05.019.

- 13 [37] D. Drygin, A. Siddiqui-Jain, S. O'Brien, M. Schwaebe, A. Lin, J. Bliesath, C.B. Ho, C.
14 Proffitt, K. Trent, J.P. Whitten, J.K. Lim, D. Von Hoff, K. Anderes, W.G. Rice, Anticancer
15 activity of CX-3543: a direct inhibitor of rRNA biogenesis, *Cancer Res.* 69 (2009) 7653–
16 7661. doi:10.1158/0008-5472.CAN-09-1304.

- 17 [38] D. Drygin, A. Lin, J. Bliesath, C.B. Ho, S.E. O'Brien, C. Proffitt, M. Omori, M. Haddach,
18 M.K. Schwaebe, A. Siddiqui-Jain, N. Streiner, J.E. Quin, E. Sanij, M.J. Bywater, R.D.
19 Hannan, D. Ryckman, K. Anderes, W.G. Rice, Targeting RNA polymerase I with an oral
20 small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth,
21 *Cancer Res.* 71 (2011) 1418–1430. doi:10.1158/0008-5472.CAN-10-1728.

- 22 [39] K. Peltonen, L. Colis, H. Liu, R. Trivedi, M.S. Moubarek, H.M. Moore, B. Bai, M.A.
23 Rudek, C.J. Bieberich, M. Laiho, A targeting modality for destruction of RNA polymerase
24 I that possesses anticancer activity, *Cancer Cell.* 25 (2014) 77–90.

doi:10.1016/j.ccr.2013.12.009.

- [40] K. Peltonen, L. Colis, H. Liu, S. Jäämaa, H.M. Moore, J. Enbäck, P. Laakkonen, A. Vaahtokari, R.J. Jones, T.M. af Hällström, M. Laiho, Identification of novel p53 Pathway activating Small-molecule compounds reveals unexpected similarities with known therapeutic agents, *PLoS One*. 5 (2010) 1–11. doi:10.1371/journal.pone.0012996.
- [41] H. Xu, M. Di Antonio, S. McKinney, V. Mathew, B. Ho, N.J. O’Neil, N. Dos Santos, J. Silvester, V. Wei, J. Garcia, F. Kabeer, D. Lai, P. Soriano, J. Banáth, D.S. Chiu, D. Yap, D.D. Le, F.B. Ye, A. Zhang, K. Thu, J. Soong, S.C. Lin, A.H.C. Tsai, T. Osako, T. Algara, D.N. Saunders, J. Wong, J. Xian, M.B. Bally, J.D. Brenton, G.W. Brown, S.P. Shah, D. Cescon, T.W. Mak, C. Caldas, P.C. Stirling, P. Hieter, S. Balasubramanian, S. Aparicio, CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours, *Nat. Commun.* 8 (2017). doi:10.1038/ncomms14432.
- [42] S.S. Negi, P. Brown, rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis, *Oncotarget*. 6 (2015). doi:10.18632/oncotarget.4093.
- [43] N. Hein, D.P. Cameron, K.M. Hannan, N.Y.N. Nguyen, C.Y. Fong, J. Sornkom, M. Wall, M. Pavy, C. Cullinane, J. Diesch, J.R. Devlin, A.J. George, E. Sanij, J. Quin, G. Poortinga, I. Verbrugge, A. Baker, D. Drygin, S.J. Harrison, J.D. Rozario, J.A. Powell, S.M. Pitson, J. Zuber, R.W. Johnstone, M.A. Dawson, M.A. Guthridge, A. Wei, G.A. McArthur, R.B. Pearson, R.D. Hannan, Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population, *Blood*. 129 (2017) 2882–2895. doi:10.1182/blood-2016-05-718171.
- [44] H.C. Lee, H. Wang, V. Baladandayuthapani, H. Lin, J. He, R.J. Jones, I. Kuitse, D. Gu, Z. Wang, W. Ma, J. Lim, S. O’Brien, J. Keats, J. Yang, R.E. Davis, R.Z. Orlowski, RNA

- Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma, *Br. J. Haematol.* 177 (2017) 80–94. doi:10.1111/bjh.14525.
- [45] M.G. Lawrence, D. Obinata, S. Sandhu, L.A. Selth, S.Q. Wong, L.H. Porter, N. Lister, D. Pook, C.J. Pezaro, D.L. Goode, R.J. Rebello, A.K. Clark, M. Papargiris, J. Van Gramberg, A.R. Hanson, P. Banks, H. Wang, B. Niranjana, S. Keerthikumar, S. Hedwards, A. Huglo, R. Yang, C. Henzler, Y. Li, F. Lopez-Campos, E. Castro, R. Toivanen, A. Azad, D. Bolton, J. Goad, J. Grummet, L. Harewood, J. Kourambas, N. Lawrentschuk, D. Moon, D.G. Murphy, S. Sengupta, R. Snow, H. Thorne, C. Mitchell, J. Pedersen, D. Clouston, S. Norden, A. Ryan, S.M. Dehm, W.D. Tilley, R.B. Pearson, R.D. Hannan, M. Frydenberg, L. Furic, R.A. Taylor, G.P. Risbridger, Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy, *Eur. Urol.* 74 (2018) 573–574. doi:10.1016/j.eururo.2018.06.020.
- [46] L. Li, Y. Li, J. Zhao, S. Fan, L. Wang, X. Li, CX-5461 induces autophagy and inhibits tumor growth via mammalian target of rapamycin-related signaling pathways in osteosarcoma, *Onco. Targets. Ther.* 9 (2016) 5985–5997. doi:10.2147/OTT.S104513.
- [47] R. Cornelison, Z.C. Dobbin, A.A. Katre, D.H. Jeong, Y. Zhang, D. Chen, Y. Petrova, D.C. Llaneza, A.D. Steg, L. Parsons, D.A. Schneider, C.N. Landen, Targeting RNA-polymerase I in both chemosensitive and chemoresistant populations in epithelial ovarian cancer, *Clin. Cancer Res.* 23 (2017) 6529–6540. doi:10.1158/1078-0432.CCR-17-0282.
- [48] R. Niemas-Teshiba, R. Matsuno, L.L. Wang, X.X. Tang, B. Chiu, J. Zeki, J. Coburn, K. Ornell, A. Naranjo, C. Van Ryn, W.B. London, M.D. Hogarty, J.M. Gastier-Foster, A.T. Look, J.R. Park, J.M. Maris, S.L. Cohn, R.C. Seeger, S. Asgharzadeh, N. Ikegaki, H. Shimada, MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI

neuroblastomas: a report from the children's oncology group., *Oncotarget*. 9 (2018) 6416–6432. doi:10.18632/oncotarget.23740.

[49] D.G. Pestov, Z. Strezoska, L.F. Lau, Evidence of p53-Dependent Cross-Talk between Ribosome Biogenesis and the Cell Cycle: Effects of Nucleolar Protein Bop1 on G1/S Transition, *Mol. Cell. Biol.* 21 (2001) 4246–4255. doi:10.1128/MCB.21.13.4246-4255.2001.

[50] Y. Liu, C. Deisenroth, Y. Zhang, RP-MDM2-p53 Pathway: Linking Ribosomal Biogenesis and Tumor Surveillance, *Trends in Cancer*. 2 (2016) 191–204. doi:10.1016/j.trecan.2016.03.002.

[51] K.E. Sloan, M.T. Bohnsack, N.J. Watkins, The 5S RNP Couples p53 Homeostasis to Ribosome Biogenesis and Nucleolar Stress, *Cell Rep.* 5 (2013) 237–247. doi:10.1016/j.celrep.2013.08.049.

[52] G. Donati, S. Peddigari, C.A. Mercer, G. Thomas, 5S Ribosomal RNA Is an Essential Component of a Nascent Ribosomal Precursor Complex that Regulates the Hdm2-p53 Checkpoint, *Cell Rep.* 4 (2013) 87–98. doi:10.1016/j.celrep.2013.05.045.

[53] N. Ban, R. Beckmann, J.H.D. Cate, J.D. Dinman, F. Dragon, S.R. Ellis, D.L.J. Lafontaine, L. Lindahl, A. Liljas, J.M. Lipton, M.A. McAlear, P.B. Moore, H.F. Noller, J. Ortega, V.G. Panse, V. Ramakrishnan, C.M.T. Spahn, T.A. Steitz, M. Tchorzewski, D. Tollervy, A.J. Warren, J.R. Williamson, D. Wilson, A. Yonath, M. Yusupov, A new system for naming ribosomal proteins., *Curr. Opin. Struct. Biol.* 24 (2014) 165–9. doi:10.1016/j.sbi.2014.01.002.

[54] A.J. Pickard, U. Bierbach, The cell's nucleolus: an emerging target for chemotherapeutic intervention., *ChemMedChem*. 8 (2013) 1441–9. doi:10.1002/cmdc.201300262.

[55] Y.-L. Yao, W.-M. Yang, Nuclear proteins: promising targets for cancer drugs., *Curr. Cancer*

1 Drug Targets. 5 (2005) 595–610. <http://www.ncbi.nlm.nih.gov/pubmed/16375665>

2 (accessed September 5, 2018).

3 [56] J.-L. Langhendries, E. Nicolas, G. Doumont, S. Goldman, D.L.J. Lafontaine, J.-L.

4 Langhendries, E. Nicolas, G. Doumont, S. Goldman, D.L.J. Lafontaine, The human box

5 C/D snoRNAs U3 and U8 are required for pre-rRNA processing and tumorigenesis,

6 Oncotarget. 5 (2016) 3–8. doi:10.18632/oncotarget.11148.

7 [57] H. Su, T. Xu, S. Ganapathy, M. Shadfan, M. Long, T.H. Huang, I. Thompson, Z.M. Yuan,

8 Elevated snoRNA biogenesis is essential in breast cancer, Oncogene. 33 (2014) 1348–

9 1358. doi:10.1038/onc.2013.89.

10 [58] G. Zisser, U. Ohmayer, C. Mauerhofer, V. Mitterer, I. Klein, G.N. Rechberger, H.

11 Wolinski, M. Prattes, B. Pertschy, P. Milkereit, H. Bergler, Viewing pre-60S maturation at

12 a minute’s timescale., Nucleic Acids Res. 46 (2018) 3140–3151. doi:10.1093/nar/gkx1293.

13 [59] S. Tahmasebi, A. Khoutorsky, M.B. Mathews, N. Sonenberg, Translation deregulation in

14 human disease., Nat. Rev. Mol. Cell Biol. (2018). doi:10.1038/s41580-018-0034-x.

15 [60] S. Pellegrino, M. Meyer, C. Zorbas, S.A. Bouchta, K. Saraf, S.C. Pelly, G. Yusupova, A.

16 Evidente, V. Mathieu, A. Kornienko, D.L.J. Lafontaine, M. Yusupov, The Amaryllidaceae

17 Alkaloid Haemanthamine Binds the Eukaryotic Ribosome to Repress Cancer Cell Growth,

18 Structure. 26 (2018) 416–425.e4. doi:10.1016/j.str.2018.01.009.

19 [61] J.R. Devlin, K.M. Hannan, N. Hein, C. Cullinane, E. Kusnadi, P.Y. Ng, A.J. George, J.

20 Shortt, M.J. Bywater, G. Poortinga, E. Sanij, J. Kang, D. Drygin, S. O’Brien, R.W.

21 Johnstone, G.A. McArthur, R.D. Hannan, R.B. Pearson, Combination therapy targeting

22 ribosome biogenesis and mRNA translation synergistically extends survival in MYC-

23 driven lymphoma, Cancer Discov. 6 (2016) 59–70. doi:10.1158/2159-8290.CD-14-0673.

24 [62] Y.W. Lam, A.I. Lamond, M. Mann, J.S. Andersen, Analysis of Nucleolar Protein Dynamics

- Reveals the Nuclear Degradation of Ribosomal Proteins, *Curr. Biol.* 17 (2007) 749–760.
doi:10.1016/j.cub.2007.03.064.
- [63] S. Xue, M. Barna, Specialized ribosomes: a new frontier in gene regulation and organismal biology, *Nat Rev Mol Cell Biol.* 13 (2012) 355–369. doi:10.1038/nrm3359.
- [64] N. Slavov, S. Semrau, E. Airoidi, B. Budnik, A. van Oudenaarden, Differential Stoichiometry among Core Ribosomal Proteins, *Cell Rep.* 13 (2015) 865–873.
doi:10.1016/j.celrep.2015.09.056.
- [65] A.S. Lee, R. Burdeinick-Kerr, S.P. Whelan, A ribosome-specialized translation initiation pathway is required for cap-dependent translation of vesicular stomatitis virus mRNAs, *Proc Natl Acad Sci U S A.* 110 (2013) 324–329. doi:10.1073/pnas.1216454109.
- [66] M.N. O’Leary, K.H. Schreiber, Y. Zhang, A.C. Duc, S. Rao, J.S. Hale, E.C. Academia, S.R. Shah, J.F. Morton, C.A. Holstein, D.B. Martin, M. Kaeberlein, W.C. Ladiges, P.J. Fink, V.L. Mackay, D.L. Wiest, B.K. Kennedy, The ribosomal protein Rpl22 controls ribosome composition by directly repressing expression of its own paralog, Rpl22l1, *PLoS Genet.* 9 (2013) e1003708. doi:10.1371/journal.pgen.1003708.
- [67] Y. Zhang, A.C. Duc, S. Rao, X.L. Sun, A.N. Bilbee, M. Rhodes, Q. Li, D.J. Kappes, J. Rhodes, D.L. Wiest, Control of hematopoietic stem cell emergence by antagonistic functions of ribosomal protein paralogs, *Dev Cell.* 24 (2013) 411–425.
doi:10.1016/j.devcel.2013.01.018.
- [68] G. Fuchs, A.N. Petrov, C.D. Marceau, L.M. Popov, J. Chen, S.E. O’Leary, R. Wang, J.E. Carette, P. Sarnow, J.D. Puglisi, Kinetic pathway of 40S ribosomal subunit recruitment to hepatitis C virus internal ribosome entry site, *Proc Natl Acad Sci U S A.* 112 (2015) 319–325. doi:10.1073/pnas.1421328111.
- [69] S. Belin, A. Beghin, E. Solano-Gonzalez, L. Bezin, S. Brunet-Manquat, J. Textoris, A.C.

- Prats, H.C. Mertani, C. Dumontet, J.J. Diaz, Dysregulation of ribosome biogenesis and translational capacity is associated with tumor progression of human breast cancer cells, *PLoS One*. 4 (2009) e7147. doi:10.1371/journal.pone.0007147.
- [70] V. Marcel, S.E. Ghayad, S. Belin, G. Therizols, A.P. Morel, E. Solano-González, J.A. Vendrell, S. Hacot, H.C. Mertani, M.A. Albaret, J.C. Bourdon, L. Jordan, A. Thompson, Y. Tafer, R. Cong, P. Bouvet, J.C. Saurin, F. Catez, A.C. Prats, A. Puisieux, J.J. Diaz, P53 Acts as a Safeguard of Translational Control by Regulating Fibrillarin and rRNA Methylation in Cancer, *Cancer Cell*. 24 (2013) 318–330. doi:10.1016/j.ccr.2013.08.013.
- [71] J. Eroles, V. Marchand, B. Panthu, S. Gillot, S. Belin, S.E. Ghayad, M. Garcia, F. Laforêts, V. Marcel, A. Baudin-Baillieu, P. Bertin, Y. Couté, A. Adrait, M. Meyer, G. Therizols, M. Yusupov, O. Namy, T. Ohlmann, Y. Motorin, F. Catez, J.-J. Diaz, Evidence for rRNA 2'-O-methylation plasticity: Control of intrinsic translational capabilities of human ribosomes, *Proc. Natl. Acad. Sci.* 114 (2017) 12934–12939. doi:10.1073/pnas.1707674114.
- [72] C. Bellodi, M. McMahon, A. Contreras, D. Juliano, N. Kopmar, T. Nakamura, D. Maltby, A. Burlingame, S.A. Savage, A. Shimamura, D. Ruggero, H/ACA small RNA dysfunctions in disease reveal key roles for noncoding RNA modifications in hematopoietic stem cell differentiation, *Cell Rep*. 3 (2013) 1493–1502. doi:10.1016/j.celrep.2013.04.030.
- [73] S. Sharma, V. Marchand, Y. Motorin, D.L.J. Lafontaine, Identification of sites of 2'-O-methylation vulnerability in human ribosomal RNAs by systematic mapping, *Sci. Rep.* 7 (2017) 1–15. doi:10.1038/s41598-017-09734-9.
- [74] M. Penzo, L. Montanaro, Turning uridines around: Role of rRNA pseudouridylation in ribosome biogenesis and ribosomal function, *Biomolecules*. 8 (2018) 1–10. doi:10.3390/biom8020038.
- [75] V. Marchand, F. Blanloeil-Oillo, M. Helm, Y. Motorin, Illumina-based RiboMethSeq

approach for mapping of 2'-O-Me residues in RNA, *Nucleic Acids Res.* 44 (2016).

doi:10.1093/nar/gkw547.

- [76] N. Krogh, M.D. Jansson, S.J. Häfner, D. Tehler, U. Birkedal, M. Christensen-Dalsgaard, A.H. Lund, H. Nielsen, Profiling of 2'-O-Me in human rRNA reveals a subset of fractionally modified positions and provides evidence for ribosome heterogeneity, *Nucleic Acids Res.* 44 (2016) 7884–7895. doi:10.1093/nar/gkw482.

- [77] U. Birkedal, M. Christensen-Dalsgaard, N. Krogh, R. Sabarinathan, J. Gorodkin, H. Nielsen, Profiling of ribose methylations in RNA by high-throughput sequencing, *Angew. Chemie - Int. Ed.* 54 (2015) 451–455. doi:10.1002/anie.201408362.

- [78] V. Marcel, F. Catez, J.J. Diaz, Ribosomes: the future of targeted therapies?, *Oncotarget.* 4 (2013) 1554–1555. <http://www.ncbi.nlm.nih.gov/pubmed/24145310>.

- [79] V. Marcel, F. Catez, J.J. Diaz, P53, a translational regulator: Contribution to its tumour-suppressor activity, *Oncogene.* 34 (2015) 5513–5523. doi:10.1038/onc.2015.25.

- [80] V. Marcel, F. Catez, H.C. Mertani, J.J. Diaz, [The ribosome: a new player in tumorigenesis?], *Med Sci.* 30 (2014) 21–24. doi:10.1051/medsci/20143001006.

- [81] W. Sornjai, P. Lithanatudom, J. Eroles, P. Joly, A. Francina, S. Hacot, S. Fucharoen, S. Svasti, J.J. Diaz, H.C. Mertani, D.R. Smith, Hypermethylation of 28S ribosomal RNA in beta-thalassemia trait carriers, *Int J Biol Macromol.* 94 (2017) 728–734. doi:10.1016/j.ijbiomac.2016.10.039.

- [82] S. Weingarten-Gabbay, S. Elias-Kirma, R. Nir, A.A. Gritsenko, N. Stern-Ginossar, Z. Yakhini, A. Weinberger, E. Segal, Comparative genetics. Systematic discovery of cap-independent translation sequences in human and viral genomes, *Science* (80-.). 351 (2016). doi:10.1126/science.aad4939.

- [83] A. Yoon, G. Peng, Y. Brandenburger, O. Zollo, W. Xu, E. Rego, D. Ruggero, Y.

- 1 Brandenburg, O. Zollo, W. Xu, E. Rego, D. Ruggero, Impaired control of IRES-mediated
- 2 translation in X-linked dyskeratosis congenita, *Science* (80-.). 312 (2006) 902–906.
- 3 doi:10.1126/science.1123835.
- 4 [84] M. Penzo, L. Rocchi, S. Brugiére, D. Carnicelli, C. Onofrillo, Y. Coute, M. Brigotti, L.
- 5 Montanaro, Human ribosomes from cells with reduced dyskerin levels are intrinsically
- 6 altered in translation, *FASEB J.* 29 (2015) 3472–3482. doi:10.1096/fj.15-270991.
- 7 [85] W.A. Decatur, M.J. Fournier, rRNA modifications and ribosome function, *Trends Biochem*
- 8 *Sci.* 27 (2002) 344–351. <https://www.ncbi.nlm.nih.gov/pubmed/12114023>.
- 9 [86] P. Monaco, V. Marcel, J.-J. Diaz, F. Catez, 2'-O-Methylation of Ribosomal RNA: Towards
- 10 an Epitranscriptomic Control of Translation?, *Biomolecules.* 8 (2018) 106.
- 11 doi:10.3390/biom8040106.
- 12 [87] N.J. Watkins, M.T. Bohnsack, The box C/D and H/ACA snoRNPs: key players in the
- 13 modification, processing and the dynamic folding of ribosomal RNA, *Wiley Interdiscip*
- 14 *Rev RNA.* 3 (2012) 397–414. doi:10.1002/wrna.117.
- 15 [88] U. Rodriguez-Corona, M. Sobol, L.C. Rodriguez-Zapata, P. Hozak, E. Castano, Fibrillarin
- 16 from Archaea to human, *Biol Cell.* 107 (2015) 159–174. doi:10.1111/boc.201400077.
- 17 [89] N. Vázquez-Laslop, A.S. Mankin, How Macrolide Antibiotics Work, *Trends Biochem. Sci.*
- 18 43 (2018) 668–684. doi:10.1016/j.tibs.2018.06.011.
- 19 [90] J. Lin, D. Zhou, T.A. Steitz, Y.S. Polikanov, M.G. Gagnon, Ribosome-Targeting
- 20 Antibiotics: Modes of Action, Mechanisms of Resistance, and Implications for Drug
- 21 Design, *Annu. Rev. Biochem.* 87 (2018) 451–478. doi:10.1146/annurev-biochem-062917-
- 22 011942.
- 23 [91] E. Svidritskiy, C. Ling, D.N. Ermolenko, A.A. Korostelev, Blasticidin S inhibits translation
- 24 by trapping deformed tRNA on the ribosome, *Proc. Natl. Acad. Sci.* 110 (2013) 12283–

12288. doi:10.1073/pnas.1304922110.
- [92] N. Garreau de Loubresse, I. Prokhorova, W. Holtkamp, M. V Rodnina, G. Yusupova, M. Yusupov, Structural basis for the inhibition of the eukaryotic ribosome, *Nature*. 513 (2014) 517–522. doi:10.1038/nature13737.
- [93] I. Prokhorova, R.B. Altman, M. Djumagulov, J.P. Shrestha, A. Urzhumtsev, A. Ferguson, C.-W.T. Chang, M. Yusupov, S.C. Blanchard, G. Yusupova, Aminoglycoside interactions and impacts on the eukaryotic ribosome, *Proc. Natl. Acad. Sci.* 114 (2017) E10899–E10908. doi:10.1073/pnas.1715501114.
- [94] L. Jenner, A.L. Starosta, D.S. Terry, A. Mikolajka, L. Filonava, M. Yusupov, S.C. Blanchard, D.N. Wilson, G. Yusupova, Structural basis for potent inhibitory activity of the antibiotic tigecycline during protein synthesis., *Proc. Natl. Acad. Sci. U. S. A.* 110 (2013) 3812–6. doi:10.1073/pnas.1216691110.
- [95] A.G. Myasnikov, S. Kundhavai Natchiar, M. Nebout, I. Hazemann, V. Imbert, H. Khatter, J.-F.F. Peyron, B.P. Klaholz, Structure-function insights reveal the human ribosome as a cancer target for antibiotics, *Nat. Commun.* 7 (2016) 1–8. doi:10.1038/ncomms12856.
- [96] J. Poehlsgaard, S. Douthwaite, The bacterial ribosome as a target for antibiotics, *Nat. Rev. Microbiol.* 3 (2005) 870–881. doi:10.1038/nrmicro1265.
- [97] S.T. Mullineux, D.L. Lafontaine, Mapping the cleavage sites on mammalian pre-rRNAs: where do we stand?, *Biochimie.* 94 (2012) 1521–1532. doi:10.1016/j.biochi.2012.02.001.
- [98] K.E. Sloan, A.S. Warda, S. Sharma, K.-D. Entian, D.L.J. Lafontaine, M.T. Bohnsack, Tuning the ribosome: The influence of rRNA modification on eukaryotic ribosome biogenesis and function, *RNA Biol.* 14 (2017) 1138–1152. doi:10.1080/15476286.2016.1259781.

1
2
3

Figure legends

Figure 1. Actionable steps of human ribosome biogenesis and function in anticancer therapeutics.

Ribosome biogenesis starts in the nucleolus which forms around rDNA genes (up to 400 copies per cells in humans). A single pre-rRNA containing the 18S, 5.8S and 28S rRNA is synthesized by RNA Pol I. The processing of this pre-rRNA includes numerous cleavage steps that produce the mature 5' and 3' ends of each rRNA [97], and the addition of > 200 chemical modifications (2'-O-methylation, pseudouridylation, base acetylation, methylation, and aminocarboxypropylation) [98]. Concomitantly, these assemble with the 5S rRNA (synthesized in the nucleoplasm by RNA Pol III) and 80 r-proteins. These nuclear steps lead to the formation of pre-ribosomal subunits that are exported to the cytoplasm through nuclear pore complexes. In the cytoplasm, several quality control steps take place ensuring the capacity of the subunits to translate mRNAs. As detailed in the text, ribosome production and function can be pharmacologically targeted at several steps to preferentially kill cancer cells. The boxes illustrate some of the strategies and compounds that are currently being evaluated as therapeutic approaches, or that could be used in the future.